Cost‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer
Jacqueline N. Chu(Massachusetts General Hospital), Chin Hur(Columbia University Irving Medical Center), Angela C. Tramontano(Massachusetts General Hospital), James A. Torchia(Dana-Farber Cancer Institute), Justin F. Gainor(Harvard University), Daniel C. Chung(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Jin Choi(Massachusetts General Hospital), Sassan Ostvar(Massachusetts General Hospital), Kerry L. Reynolds(Massachusetts General Hospital)
Cited by 36
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k